Claire C Bristow1, Segundo R Leon, Emily Huang, Lourdes B Ramos, Silver K Vargas, Juan A Flores, Kelika A Konda, Carlos F Caceres, Jeffrey D Klausner. 1. From the *Division of Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA; †Unit of Health, Sexuality and Human Development, and Laboratory of Sexual Health, Universidad Peruana Cayetano Heredia, Lima, Peru; ‡Department of Global Health, University of Washington, Seattle, WA; §Division of Infectious Disease: Global Health, Department of Medicine, University of California Los Angeles, Los Angeles, CA.
Abstract
BACKGROUND: Integrated prevention for HIV and syphilis is warranted because both syphilis and HIV infections have evidence-based, scalable interventions using current health care mechanisms. The advent of dual rapid point-of-care tests, single devices that can detect multiple infections using the same specimen, provides the opportunity to integrate the screening of syphilis into HIV prevention programs, potentially increasing the numbers of people tested and allowing for same-day testing and treatment. The aim of our study was to evaluate the MedMira Multiplo Rapid TP/HIV Antibody Test (MedMira Inc, Halifax, Nova Scotia, Canada), a qualitative, rapid immunoassay that detects antibodies to Treponema pallidum and HIV. METHODS: The reference test for comparison to the T. pallidum component of the Multiplo TP/HIV Test was the T. pallidum particle agglutination assay. For the HIV component, the reference test included a fourth-generation enzyme immunoassay with a confirmatory Western blot test. RESULTS: The sensitivity and specificity for the HIV antibody component were 93.8% (95% confidence interval [CI], 69.8%-99.8%) and 100% (95% CI, 97.7%-100%), respectively. The T. pallidum component of the test had a sensitivity of 81.0% (95% CI, 68.1%-94.6%) and a specificity of 100% (95% CI, 97.6%-100%). CONCLUSIONS: Our study showed excellent performance of the HIV antibody component of the test and very good performance for the T. pallidum antibody component of the MedMira Multiplo Rapid TP/HIV Antibody Test, which should be considered to improve screening coverage. Use of effective dual tests will create improved access to more comprehensive care by integrating the screening of syphilis into HIV prevention programs.
BACKGROUND: Integrated prevention for HIV and syphilis is warranted because both syphilis and HIV infections have evidence-based, scalable interventions using current health care mechanisms. The advent of dual rapid point-of-care tests, single devices that can detect multiple infections using the same specimen, provides the opportunity to integrate the screening of syphilis into HIV prevention programs, potentially increasing the numbers of people tested and allowing for same-day testing and treatment. The aim of our study was to evaluate the MedMira Multiplo Rapid TP/HIV Antibody Test (MedMira Inc, Halifax, Nova Scotia, Canada), a qualitative, rapid immunoassay that detects antibodies to Treponema pallidum and HIV. METHODS: The reference test for comparison to the T. pallidum component of the Multiplo TP/HIV Test was the T. pallidum particle agglutination assay. For the HIV component, the reference test included a fourth-generation enzyme immunoassay with a confirmatory Western blot test. RESULTS: The sensitivity and specificity for the HIV antibody component were 93.8% (95% confidence interval [CI], 69.8%-99.8%) and 100% (95% CI, 97.7%-100%), respectively. The T. pallidum component of the test had a sensitivity of 81.0% (95% CI, 68.1%-94.6%) and a specificity of 100% (95% CI, 97.6%-100%). CONCLUSIONS: Our study showed excellent performance of the HIV antibody component of the test and very good performance for the T. pallidum antibody component of the MedMira Multiplo Rapid TP/HIV Antibody Test, which should be considered to improve screening coverage. Use of effective dual tests will create improved access to more comprehensive care by integrating the screening of syphilis into HIV prevention programs.
Authors: Joseph D Tucker; Jin Bu; Lillian B Brown; Yue-Pin Yin; Xiang-Sheng Chen; Myron S Cohen Journal: Lancet Infect Dis Date: 2010-06 Impact factor: 25.071
Authors: Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman Journal: Clin Infect Dis Date: 2011-03-15 Impact factor: 9.079
Authors: Jorge Sanchez; Javier R Lama; Jesus Peinado; Andres Paredes; Aldo Lucchetti; Kevin Russell; Tadeusz Kochel; Jose L Sebastian Journal: J Acquir Immune Defic Syndr Date: 2009-05-01 Impact factor: 3.731
Authors: Claire C Bristow; Yaw Adu-Sarkodie; Raphael O Ondondo; Elizabeth Anne Bukusi; Claver Anoumou Dagnra; Khin Yi Oo; Eh Htoo Pe; Chanthavysouk Khamsay; Le Thi Houng; Roberto Vázquez Campuzano; Jason Estes; Jeffrey D Klausner Journal: Open Forum Infect Dis Date: 2014-05-27 Impact factor: 3.835
Authors: Sasha Herbst de Cortina; Claire C Bristow; Romney Humphries; Silver Keith Vargas; Kelika A Konda; Carlos F Caceres; Jeffrey D Klausner Journal: Sex Transm Dis Date: 2017-07 Impact factor: 2.830
Authors: Ethan Osias; Phoebe Hung; Lorenzo Giacani; Chrysovalantis Stafylis; Kelika A Konda; Silver K Vargas; E Michael Reyes-Díaz; W Scott Comulada; David A Haake; Austin M Haynes; Carlos F Caceres; Jeffrey D Klausner Journal: BMC Infect Dis Date: 2020-06-23 Impact factor: 3.090
Authors: Harriet D Gliddon; Rosanna W Peeling; Mary L Kamb; Igor Toskin; Teodora E Wi; Melanie M Taylor Journal: Sex Transm Infect Date: 2017-07-26 Impact factor: 3.519
Authors: S Herbst de Cortina; C C Bristow; S K Vargas; D G Perez; K A Konda; C F Caceres; J D Klausner Journal: J Clin Microbiol Date: 2016-05-04 Impact factor: 5.948